BIOVECTRA

Some workers at Biovectra are losing their jobs, and the P.E.I. government says it's still trying to figure out what the effects will be locally.

SANTA CLARA, California, March 11, 2026 - Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding ca

CHARLOTTETOWN, PEI and WORCESTER, MA - November 6, 2025 - BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platfo

CHARLOTTETOWN, Prince Edward Island - BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma

Agilent Technologies has completed its acquisition of BIOVECTRA, a Canada-based CDMO specializing in biologics, highly potent APIs, and other molecules for targeted therapeutics. Learn more about this strategic acquisition and its impact on our capabiliti

BioVectra is a biotechnology and pharmaceutical CDMO.

By Daniella Parra Agilent Technologies (NYSE: A) said it's acquiring BIOVECTRA, a Canadian CDMO, for $925 million. The company said it will enhance Agilent's biopharma solutions by expanding service offerings, adding expertise in fast-growing segments lik

Agilent Technologies announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. BIOVECTRA produces biologics, highly potent active pharmaceutical ingred

Agilent has boosted its CDMO capacity with a $92m deal to buy Biovectra, adding expertise in GLP-1 agonists, ADCs, and cancer drugs.

Canada-based Biovectra offers fill-and-finish services for drug manufacturers. It also operates a business that makes active ingredients for complex drugs and has expertise in fast-growing segments such as the GLP-1 weight loss drugs, Agilent said.